Cargando…
Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride
Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m(2). The aim of the present work was to develop sta...
Autores principales: | Khaira, Rekha, Sharma, Jyoti, Saini, Vinay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925564/ https://www.ncbi.nlm.nih.gov/pubmed/24592173 http://dx.doi.org/10.1155/2014/560962 |
Ejemplares similares
-
Development and Characterization of In Situ Oral Gel of Spiramycin
por: Sharma, Avinash, et al.
Publicado: (2014) -
Poly(N-vinylcaprolactam) containing solid lipid polymer hybrid nanoparticles for controlled delivery of a hydrophilic drug gemcitabine hydrochloride
por: Surapaneni, Sai Geetika, et al.
Publicado: (2022) -
Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery
por: Bhattacharya, Sankha, et al.
Publicado: (2022) -
Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma
por: Nair, Anroop B., et al.
Publicado: (2019) -
Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles
por: Malfanti, Alessio, et al.
Publicado: (2016)